AUTHOREA
Log in
Sign Up
Browse Preprints
LOG IN
SIGN UP
Agnė Čerkauskaitė
Public Documents
1
COMPLEMENT INHIBITOR ECULIZUMAB IN ATYPICAL HEMOLYTIC-UREMIC SYNDROME: SINGLE CENTER...
Monika Vitkauskaitė
and 6 more
October 04, 2021
Our case series showed that eculizumab is efficacious and safe in treating atypical hemolytic-uremic syndrome, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines.